Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)
Dizal Pharmaceuticals
Dizal Pharmaceuticals
Eli Lilly and Company
Bristol-Myers Squibb
Janssen Research & Development, LLC
Hoffmann-La Roche
Bristol-Myers Squibb
Celgene
Astex Pharmaceuticals, Inc.
Pfizer
Stemline Therapeutics, Inc.
Ipsen
Eisai Inc.
Hoffmann-La Roche
BeiGene
Gilead Sciences
Children's Oncology Group
Pharmacyclics LLC.
Amgen